Stockpickr! Your Source for Stock Ideas

Comments for CVD

Added By	Comments	Type	Date Added
kirk48	been good so far	Love	February 28, 2008
gvphubli	Earnings Stability Rating: 3. Clinical trial provider’s earnings growth rate is expected to hold firm in 2008. Five-year earnings growth rate: 23%.	Love	January 28, 2008
Stepford	Clinical trials company - organizes them and compiles results data.	Love	January 19, 2008
barrons2	Cramer's favorite in this space is Covance (CVD). Covance, Cramer said, handles early and late stage testing and has a solid customer base. The company also has an immaculate balance sheet, according to Cramer. Covance has $250 million in cash, no debt and $300 million in expected free cash flow over the next two years. Cramer sees the potential for Covance to trade at 37 times this year's earnings, which translates to a target price of $115, or a 33% upside. Despite being just $1 off its 52-week high, Cramer said Covance "must be bought on any weakness."	Love	January 17, 2008
KJMarino	CRO both stages	Love	January 16, 2008
barrons2	"With an approaching U.S. presidential election in which health care will be a major issue, the drug makers are clearly in the political cross-hairs. That can only accelerate the flow of new drug testing to the CROs, making Covance and PPD good long-term bets."	Love	November 10, 2007
abedneg06	great cashflow and margins driven with revenues driven by increasing outsourcing of R&D by big pharma	Love	September 20, 2007
supratrade	BUY	Love	August 09, 2007
HungryJoe	like the biz model	Love	May 18, 2007
llaz100645	healthcare	Love	February 08, 2007
Anthony Maceroli	Drug companies must test new drugs Outsourcing to a specialized firm makes sense Covance is the leader Strong fundamentals	Love	February 02, 2007
gymir	watching - not sure	Love	January 30, 2007